615273-28-4Relevant academic research and scientific papers
Novel iminodipyridinopyrimidine analogs, its enantiomers, its diastereomers or its pharmaceutically acceptable salt and antiviral composition against hepatitis C virus containing the same as an active ingredient
-
Paragraph 0119; 0132-0135; 0137, (2019/04/06)
The present invention relates to a novel iminodipyridinopyrimidine analogue, an enantiomer thereof, a diastereomer thereof or pharmaceutically acceptable salt thereof, and an antiviral composition for hepatitis C virus containing the same as an active com
Characterization and structure-activity relationship study of iminodipyridinopyrimidines as novel hepatitis C virus inhibitor
Park, Dong-Sik,Jo, Eunji,Choi, Jihyun,Lee, MyungEun,Kim, Soohyun,Kim, Hee-Young,Nam, Jiyon,Ahn, Sujin,Hwang, Jong Yeon,Windisch, Marc Peter
, p. 65 - 73 (2017/09/20)
Upon high-throughput screening of synthetic small molecule libraries with the infectious hepatitis C virus (HCV) cell culture system, we identified an iminodipyridinopyrimidine (IDPP) scaffold. IDPP did not inhibit HCV replication, but exhibited very potent inhibitory activity on early and late steps of HCV life cycle. Applying an intensive structure-activity relationship (SAR) study, a promising IDPP Lead compound (12c) with excellent potency (EC50 = 10 nM), high safety margin (SI > 2000), and an acceptable stability in human and rat liver microsomes (t1/2 >60 min) was identified. Overall, our results suggest that the IDPP scaffold could be used for the development of novel HCV interventions.
